- Question from Caryn: Pfizer was announcing something about Sutent being used for triple-negative breast cancer. What did they announce, and will the FDA approve its use for that purpose?
- Answers - Kathy D. Miller, M.D. Unless the announcement was just today I didn't see any new announcements about Sutent (chemical name: sunitinib) and triple-negative breast cancer. We did see the results of a phase III trial of Sutent as treatment for women with metastatic disease. That study required patients to have had previous chemotherapy with an anthracycline and a taxane, but it was not limited to patients with triple-negative disease. In that study, patients were treated either with Sutent or with an oral chemotherapy medicine called capcetabine, otherwise known as Xeloda. In that study, Xeloda was more effective, and because of that, the study was stopped early. We do know that Sutent can be effective for some women with breast cancer but in this study it was less effective than the other option. There are still other studies of Sutent that are going on, and one of those studies is focused on women with triple-negative disease, but that study is still going on, and we have not seen any results.
The Ask-the-Expert Online Conference called Updates From the 2009 San Antonio Breast Cancer Symposium featured Kathy Miller, M.D. and Kristin Brill, M.D., F.A.C.S. answering your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.
Editor's Note: This conference took place in December 2009.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.